CTRI/2023/06/054540已完成Unknown
A randomized, open-label, two-treatment, two-period, two- sequence, single-dose,balanced, crossover, comparative bioavailability study of Dynapar QPS Plus of TroikaaPharmaceuticals Ltd., India with Volini Aerosol Spray of Sun Pharmaceutical IndustriesLtd, India in healthy, adult, human subjects under fasting conditions.
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1 Subjects aged between 18 and 45 years (both inclusive) of both gender.
- •2 Subjects weight within normal range according to normal values for Body Mass Index (between 18.50 and 30.00 kg/m2) (both inclusive) with greater than equal to 50 kg weight.
- •3 Subject with hemoglobin level greater than equal to 11.5 gm percent at the time of screening.
- •4 Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within the clinically acceptable range.
- •5 Subjects having clinically acceptable 12-lead electrocardiogram (ECG).
- •6 Subjects having clinically acceptable chest X-Ray (PA view), if taken.
- •7 Subjects having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine).
- •8 Subjects having negative Urine alcohol /alcohol breath test.
- •9 Subjects who are Non-smokers.
- •10 Subjects willing to adhere to the protocol requirements and to provide written informed consent.
- •11 For male Subjects:
- •Subjects willing to follow approved birth control methods for the duration of the study as judged by the investigator(s), such as (a double barrier method) condom with spermicide, Condom with diaphragm, or abstinence. Subjects should also not donate sperm during study period.
- •12 Subjects having negative urine pregnancy test at screening and negative serum Beta-hCG Pregnancy test on admission day of period 01. (For female subject).
- •13 For Female Subjects:
- •Female of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as intrauterine device (IUD), abstinence or double barrier contraception, i.e., condom plus diaphragm, condom plus spermicidal or foam.
- •Postmenopausal for at least 1 year, or if less than 1 year, then acceptable contraceptive measures as mentioned above.
- •Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject).
排除标准
- •1 Hypersensitivity to Diclofenac or related class of drugs or any of its excipients or heparin.
- •2 History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, urogenital or psychiatric disease or disorder.
- •3 Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 30 days prior to admission of period-01.
- •4 Presence of alcoholism or drug abuse.
- •5 History or presence of asthma, urticaria or other significant allergic reactions.
- •6 History or presence of significant gastric and/or duodenal ulceration.
- •7 History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
- •8 History or presence of cancer or basal or squamous cell carcinoma.
- •9 Difficulty with donating blood.
- •10 Use of any prescribed medication or OTC medication including vaccine, vitamins and herbal remedies during last 30 days prior to admission of period 01.
- •11 Major illness within past 3 months.
- •12 Volunteer who have donated blood (1 unit) or participation in a drug research study within past 90 days prior to the first dose of the study drug.
- •13 Consumption of xanthine-containing products, tobacco containing products, alcohol or alcoholic products for within 48.00 hours prior to admission of period 01.
- •14 Consumption of grapefruit or grapefruit juice containing products within 72.00 hours prior to admission of period 01.
- •15 Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
- •16 History or presence of significant easy bruising or bleeding.
- •17 History or presence of significant recent trauma.
- •18 Any contraindication to cannulation or blood sampling.
- •19 Subjects who have been on an abnormal diet (for whatever reason) during the four weeks preceding the study.
- •20 Female subjects who are currently pregnant or breast feeding.
- •21 Subjects who have Bruises, damaged skin, eczema or wounds on the application site, or the application site inappropriate for applying the IMP as per PI discretion.
研究者
相似试验
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapsesMultiple sclerosisMedDRA version: 12.0Level: PTClassification code 10028245Term: <Manually entered code. Term in E.1.1>EUCTR2004-000555-42-DKSanofi-aventis US, Inc1,080
进行中（未招募）
1 期
To evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD)MedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852Alzheimer's diseaseEUCTR2016-002976-28-ITOVARTIS PHARMA AG1,144
进行中（未招募）
1 期
Study in patients with primary Sjögren’s syndrome with the aim to assess safety, tolerability, pharmacokinetics (way the body absorbs, distributes, and gets rid of the drug) and preliminary efficacy of CDZ173Primary Sjögren's syndromeMedDRA version: 19.0Level: PTClassification code 10040767Term: Sjogren's syndromeSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2014-004616-12-DEovartis Pharma Services AG30
进行中（未招募）
1 期
Efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney diseaseType II Diabetes Mellitus and Diabetic Kidney DiseaseMedDRA version: 21.1Level: PTClassification code 10061835Term: Diabetic nephropathySystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2015-000950-39-ITBAYER AG12,800
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group, fixed-dose, 8-weektreatment, multi-center trial evaluating the dose effect relationship for efficacy and the safety of 3 oral doses of surinabant: 2.5, 5 and 10mg/day as an aid to smoking cessation in cigarette smokers - SURSMOKEAid to smoking cessation in cigarette smokersMedDRA version: 8.1Level: LLTClassification code 10057852Term: Nicotine dependenceEUCTR2006-005334-21-DEsanofi-aventis recherche et developpement805